![]() |
|
|
Vol. 302, Issue 2, 666-671, August 2002
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan.
| |
Abstract |
|---|
|
|
|---|
Life-threatening drug interactions are known to occur between methotrexate and nonsteroidal anti-inflammatory drugs (NSAIDs), probenecid, and penicillin G. The purpose of this study was to characterize methotrexate transport, as well as to determine the site and the mechanism of drug interactions in the proximal tubule. Mouse proximal tubule cells stably expressing basolateral human organic anion transporters (hOAT1 and hOAT3) and apical hOAT (hOAT4) were established. The Km values for hOAT1-, hOAT3-, and hOAT4-mediated methotrexate uptake were 553.8 µM, 21.1 µM, and 17.8 µM, respectively. NSAIDs (salicylate, ibuprofen, ketoprofen, phenylbutazone, piroxicam, and indomethacin), probenecid, and penicillin G dose dependently inhibited methotrexate uptake mediated by hOAT1, hOAT3, and hOAT4. Kinetic analysis of inhibitory effects of these drugs on hOAT3-mediated methotrexate uptake revealed that these inhibitions were competitive. The Ki values for the effects of salicylate, phenylbutazone, indomethacin, and probenecid on hOAT3-mediated methotrexate uptake were comparable with therapeutically relevant plasma concentrations of unbound drugs. In addition, in the presence of human serum albumin, the Ki values were comparable with therapeutically relevant total plasma concentrations of drugs. In conclusion, these results suggest that methotrexate is taken up via hOAT3 and hOAT1 at the basolateral side of the proximal tubule and effluxed or taken up at the apical side via hOAT4. In addition, hOAT1, hOAT3, and hOAT4 are the sites of drug interactions between methotrexate and NSAIDs, probenecid, and penicillin G. Furthermore, it was predicted that hOAT3 is the site of drug interactions between methotrexate and salicylate, phenylbutazone, indomethacin, and probenecid in vivo.
| |
Introduction |
|---|
|
|
|---|
Methotrexate
is widely used at high dosages in the treatment of malignancies,
whereas it is used at low dosages in rheumatoid arthritis. Methotrexate
is eliminated almost entirely in an unchanged form in urine, which
involves glomerular filtration and active tubular secretion (Shen and
Azarnoff, 1978
). Therefore, renal insufficiency or drug interactions,
which reduce the clearance of methotrexate, are potentially toxic events.
Interactions between methotrexate and drugs including nonsteroidal
anti-inflammatory drugs (NSAIDs), probenecid, and penicillin G have
been reported by several groups of investigators (Ellison and Servi,
1985
; Thyss et al., 1986
; Basin et al., 1991
; Frenia and Long, 1992
;
Tracy et al., 1992
; Kremer and Hamilton, 1995
). Severe and even
life-threatening interactions have been observed, including bone marrow
suppression and acute renal failure (Ellison and Servi, 1985
; Thyss et
al., 1986
; Basin et al., 1991
; Frenia and Long, 1992
). The interactions
may have been caused by protein binding displacement, inhibitory
effects on the renal secretion of methotrexate, and a decline in
glomerular filtration as a result of inhibition of prostaglandin
synthesis (Tracy et al., 1992
; Kremer and Hamilton, 1995
). Among these
possible causes, the renal tubular secretion of methotrexate has been
thought to be a major site for drug interaction (Frenia and Long,
1992
).
Two different types of human multispecific OATs (hOAT1 and hOAT3) were
recently isolated (Reid et al., 1998
; Hosoyamada et al., 1999
; Cha et
al., 2001
). In the kidney, hOAT1 and hOAT3 are localized at the
basolateral membrane of the proximal tubule (Hosoyamada et al., 1999
;
Cha et al., 2001
). Since hOAT1 and hOAT3 mediate the transport of
various drugs, endogenous substances, and xenobiotics, these
transporters are considered to be responsible for the basolateral uptake of organic anions in renal epithelial cells. On the other hand,
OAT-K1 (Saito et al., 1996
; Masuda et al., 1999b
), OAT-K2 (Masuda et al., 1999a
), hOAT4 (Cha et al., 2000
), organic
anion-transporting peptide 1 (oatp1) (Jacquemin et al., 1994
), oatp3
(Abe et al., 1998
), multidrug-resistance protein 2 (MRP2) (Leier et
al., 2000
), and human type I sodium-dependent inorganic phosphate
transporter (NPT1) (Uchino et al., 2000
) were isolated and identified
as transporters of anionic drugs and substances at the apical membrane
of the proximal tubule.
The purpose of this study was to characterize methotrexate transport in the proximal tubule, as well as to determine the site and mechanism of interactions between methotrexate and NSAIDs, probenecid, and penicillin G using the second portion of the proximal tubule (S2) cells stably expressing hOAT1, hOAT3, and hOAT4 (S2 hOAT1, S2 hOAT3, and S2 hOAT4, respectively).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. [3H]Methotrexate (547.6 GBq/mmol) was purchased from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). Methotrexate, various NSAIDs, probenecid, penicillin G, transferrin, and human serum albumin were obtained from Sigma Chemical Co. (St. Louis, MO). Other materials used included fetal bovine serum, trypsin and geneticin from Invitrogen (Carlsbad, CA), recombinant epidermal growth factor from Wakunaga (Hiroshima, Japan), insulin from Shimizu (Shizuoka, Japan), RITC 80-7 culture medium from Iwaki Co. (Tokyo, Japan), and TfX-50 from Promega (Madison, WI).
Cell Culture and Establishment of S2 hOAT1,
S2 hOAT3, and S2 hOAT4.
S2
cells, derived from transgenic mice harboring temperature-sensitive
simian virus 40 large T-antigen gene, were established as described
previously by us (Takeda et al., 1999
). S2 is the segment
of the proximal tubule in which hOAT1, hOAT3, and hOAT4 were localized
(Hosoyamada et al., 1999
; Cha et al., 2001
; Babu et al., 2002
). The
full-length cDNAs of hOAT1, hOAT3, and hOAT4 were subcloned into pcDNA
3.1 (Invitrogen, Carlsbad, CA), a mammalian expression vector.
S2 hOAT1, S2 hOAT3, and S2 hOAT4
were obtained by transfecting S2 cells with pcDNA3.1-hOAT1,
pcDNA3.1-hOAT3, and pcDNA3.1-hOAT4 coupled with pSV2neo, a
neomycin-resistant gene, using TfX-50 according to the manufacturer's
instructions. S2 cells transfected with pcDNA3.1 lacking an
insert, and pSV2neo were designated as S2 pcDNA 3.1 and
used as a control (mock). These cells were grown in a humidified
incubator at 33°C and under 5% CO2 using RITC
80-7 medium containing 5% fetal bovine serum, 10 µg/ml transferrin,
0.08 U/ml insulin, 10 ng/ml recombinant epidermal growth factor, and
400 µg/ml Geneticin. The cells were subcultured in a medium
containing 0.05% trypsin-EDTA solution (containing 137 mM NaCl, 5.4 mM
KCl, 5.5 mM glucose, 4 mM NaHCO3, 0.5 mM EDTA,
and 5 mM Hepes, pH 7.2) and used for 10 to ~35 passages. Clonal cells
were isolated using a cloning cylinder and screened by determining the
uptake of the optimal substrate for each transporter, i.e.,
para-[14C]aminohippuric acid for
hOAT1 (Hosoyamada et al., 1999
) and [3H]estrone
sulfate for hOAT3 (Cha et al., 2001
) and hOAT4 (Cha et al., 2000
). The
S2 monolayer was determined to be leaky, based on the
results of a study in which we estimated paracellular secretion from
cells cultured on a permeable support, using
D-[3H]mannitol as an
indicator. In addition, vertical sections of S2 hOAT1,
S2 hOAT3, and S2 hOAT4 stained with polyclonal
antibodies against hOAT1, hOAT3, and hOAT4, respectively, showed that
the subcellular localization of hOAT1, hOAT3, and hOAT4 proteins was mainly on the cell membrane. Both the basolateral and apical portions of the membrane showed positive staining. Therefore, the cells were
cultured on a solid support for these experiments.
Uptake Experiments.
Uptake experiments were performed as
previously described (Takeda et al., 1999
). As described above, the
cells were cultured at 33°C, which is suitable for cell growth for
cells encoding temperature-sensitive simian virus 40 large T-antigen
gene (Takeda et al., 1999
). In contrast, uptake experiments were
performed at 37°C, which is commonly used for evaluating transporter
activities. There was no difference in the amount of uptake between
33°C and 37°C (data not shown). Based on these results, the cells
were cultured at 33°C, whereas uptake experiments were performed at 37°C. The S2 cells were seeded in 24-well tissue culture
plates at a cell density of 1 × 105cells/well. After the cells were cultured for
2 days, the cells were washed three times with Dulbecco's modified
phosphate-buffered saline (D-PBS) solution (containing 137 mM NaCl, 3 mM KCl, 8 mM NaHPO4, 1 mM
KH2PO4, 1 mM
CaCl2, and 0.5 mM MgCl2, pH
7.4), and then preincubated in the same solution for 10 min in a water
bath at 37°C. The cells were then incubated in D-PBS containing
[3H]methotrexate at various concentrations as
indicated in each experiment. The uptake was stopped by the addition of
ice-cold D-PBS, and the cells were washed three times with the same
solution. The cells in each well were lysed with 0.5 ml of 0.1 N sodium hydroxide and 2.5 ml of Aquasol-2, and radioactivity was determined using a
-scintillation counter (Aloka, Tokyo, Japan;
LSC-3100).
Inhibition Study.
To evaluate the inhibitory effects of
various NSAIDs, probenecid, and penicillin G on methotrexate uptake
mediated by hOAT1, hOAT3, and hOAT4, S2 hOAT1,
S2 hOAT3, and S2 hOAT4 were incubated in a
solution containing [3H]methotrexate in the
absence or presence of various drugs at 37°C. Considering the
Km values for hOAT1-, hOAT3-, and
hOAT4-mediated methotrexate uptake, hOAT1-, hOAT3-, and hOAT4-mediated
methotrexate uptake was estimated using a methotrexate concentration of
1 µM (hOAT1) or 100 nM (hOAT3 and hOAT4). In addition, based on the results of time course experiments (Fig.
1), hOAT3-mediated methotrexate uptake
was evaluated during the 2-min incubation. On the other hand, since the
specific methotrexate uptake activity, represented as the amount of
hOAT1- and hOAT4-mediated methotrexate uptake subtracted by that by
mock, was about two times larger during the 15-min incubation than that
during the 2-min incubation, we chose 15 min as the incubation time for
the inhibition experiments. Salicylate, probenecid, and penicillin G
were dissolved in distilled water. Ibuprofen, ketoprofen,
phenylbutazone, piroxicam, and indomethacin were dissolved in dimethyl
sulfoxide and diluted with the incubation medium. The final
concentration of dimethyl sulfoxide in the incubation medium was
adjusted to less than 1%.
|
Kinetic Analysis.
After preincubation as described above,
S2 hOAT3 was incubated in D-PBS containing
[3H]methotrexate at different concentrations in
the absence or presence of various drugs for 2 min. For the kinetic
analysis of inhibitory effects, double reciprocal plot analyses were
performed based on methotrexate under each condition (Apiwattanakul et
al., 1999
). When the inhibition was competitive, the
Ki values were calculated based on the
following equation,
|
|
|
Statistical Analysis. Data are expressed as means ± S.E. Statistical differences were determined using one-way ANOVA with Dunnett's post hoc test. Differences were considered significant at P < 0.05.
| |
Results |
|---|
|
|
|---|
Methotrexate Uptake. To evaluate the time-dependent uptake of methotrexate in S2 hOAT1, S2 hOAT3 and S2 hOAT4, S2 cell monolayers were incubated in a solution containing 1 µM methotrexate (hOAT1) or 100 nM methotrexate (hOAT3 and hOAT4) for various periods at 37°C. As shown in Fig. 1, when the amount of methotrexate uptake in mock was subtracted from those in S2 hOAT1, S2 hOAT3, and S2 hOAT4, the specific uptake in S2 hOAT1 (Fig. 1A) and S2 hOAT4 (Fig. 1C) increased in a time-dependent manner and reached steady state, whereas that in S2 hOAT3 (Fig. 1B) decreased after reaching peak. The latter may be due to the observation that nonspecific methotrexate efflux overwhelmed hOAT3-mediated methotrexate uptake depending on the nature of monoclonal cells into which hOAT3 cDNA was transfected.
The kinetics of methotrexate uptake was examined to evaluate the pharmacological characteristics of hOAT1, hOAT3, and hOAT4 on methotrexate transport. The concentration-dependent uptake of methotrexate was observed in S2 hOAT1, S2 hOAT3, and S2 hOAT4 after subtraction of uptake by mock (data not shown). As shown in Fig. 2, Eadie-Hofstee plot analysis of hOAT1-, hOAT3-, and hOAT4-mediated methotrexate uptake gave a single straight line. The estimated Km values of methotrexate uptake by hOAT1, hOAT3, and hOAT4 were 553.8 ± 43.2 µM, 21.1 ± 2.8 µM, and 17.8 ± 1.6 µM, respectively (from three determinations in one typical experiment of two separate experiments). These results suggest that hOAT1, hOAT3, and hOAT4 mediate transport of methotrexate.
|
Inhibitory Effects on Methotrexate Uptake.
We examined the
effects of various drugs on methotrexate uptake mediated by hOAT1,
hOAT3, and hOAT4. The drugs used were NSAIDs (salicylate, ibuprofen,
ketoprofen, phenylbutazone, piroxicam, and indomethacin), probenecid,
and penicillin G. These drugs inhibited methotrexate uptake mediated by
hOAT1, hOAT3, and hOAT4 in a dose-dependent manner, whereas penicillin
G did not inhibit hOAT1-mediated methotrexate uptake and salicylate did
not inhibit hOAT4-mediated methotrexate uptake (data not shown). The
effects of these NSAIDs on methotrexate uptake by hOAT1, hOAT3, and
hOAT4 are listed in Table 1.
|
Kinetic Analysis of Inhibition.
To further elucidate the
inhibitory effects of NSAIDs, probenecid, and penicillin G on
hOAT3-mediated methotrexate uptake, we have examined the inhibitory
effects of these drugs at different concentrations of methotrexate.
Typical results are shown in Fig. 3.
Analysis of a Lineweaver-Burk plot of the effects of salicylate (Fig.
3A), phenylbutazone (Fig. 3B), indomethacin (Fig. 3C), and probenecid
(Fig. 3D) on the hOAT3-mediated methotrexate uptake demonstrated that
these drugs inhibited the methotrexate uptake in a competitive manner.
The inhibitory effects of ibuprofen, ketoprofen, piroxicam, and
penicillin G were also competitive (data not shown). The
Ki values for each drug tested are
shown in Table 2. In addition, we
performed a kinetic analysis of the inhibitory effects of salicylate,
phenylbutazone, indomethacin, and probenecid on hOAT3-mediated
methotrexate uptake in the presence of 5% human serum albumin. The
inhibitory effects of these drugs on hOAT3-mediated methotrexate uptake
in the presence of 5% human serum albumin were also competitive, and
the Ki values are listed in Table 2.
|
|
| |
Discussion |
|---|
|
|
|---|
hOAT1 and hOAT3 were recently cloned and characterized as
multispecific OATs, and were found to mediate active transport of organic anions from the interstitium to the cells in the basolateral membrane of the proximal tubule (Hosoyamada et al., 1999
; Cha et al.,
2001
). Some differences in characteristics exist between hOAT1 and
hOAT3, such as substrate specificity and localization: hOAT1 at the
basolateral side of the S2 segment of the proximal tubule
(Hosoyamada et al., 1999
) versus hOAT3 at the first, second, and third
segments (S1, S2, and S3) of the
proximal tubule (Cha et al., 2001
). In addition, hOAT1, but not hOAT3,
exhibits transport properties as an exchanger (Hosoyamada et al., 1999
;
Cha et al., 2001
). On the other hand, hOAT4 is localized to the apical
membrane of the proximal tubule (Babu et al., 2002
), and hOAT4 exhibits a relatively narrow substrate specificity compared with hOAT1 and hOAT3
(Cha et al., 2000
).
Carrier-mediated transport of methotrexate in the basolateral side of
the proximal tubule was suggested based on the results of the
experiments using renal slices (Nierenberg, 1983
; Williams et al.,
1984
) or isolated proximal tubule (Besseghir et al., 1989
). The current
results suggest that hOAT3 and hOAT1 mediate the transport of
methotrexate in the basolateral side of the proximal tubule. Human OAT
cloned by Lu was designated as human kidney p-aminohippurate transporter (hPAHT) (Lu et al., 1999
), and there was 98.2% amino acid
sequence homology between hPAHT and hOAT1 (data not shown). In contrast
to hOAT1, hPAHT exhibited no significant methotrexate uptake activity.
The discrepancy in methotrexate uptake activity between hOAT1 and hPAHT
may be due to this small difference in amino acid sequence or the
experimental conditions. To clarify this, a site-directed mutagenesis
study should be performed. The current results were also consistent
with the previous results that rat OAT1 mediates methotrexate uptake
(Uwai et al., 2000
). In addition, hOAT2, which was recently identified
to be localized to the basolateral side of the proximal tubule, showed
no significant uptake activity of methotrexate (M. Takeda,
unpublished observation). This is in contrast to the recent
report that cells expressing hOAT2 showed uptake of methotrexate (Sun
et al., 2001
). The reason for the discrepancy remains unknown, and
further studies should be performed. It is also possible that
unidentified OATs other than hOAT3 and hOAT1 are also involved in
methotrexate transport in the basolateral membrane of the proximal tubule.
In addition to hOAT4, human transporters mediating the transport of
organic anions in the apical membrane of the proximal tubule have been
cloned, including MRP2 (Leier et al., 2000
) and NPT1 (Uchino et al.,
2000
). Moreover, human MRP2 was shown to mediate the efflux of
methotrexate using stable cells (Hooijberg et al., 1999
). Thus, the
relative contribution of hOAT4 and MRP2 to apical methotrexate
transport should be clarified. In addition to human transporters,
rodent transporters mediating the apical transport of organic anions
have been cloned, including OAT-K1 (Saito et al., 1996
; Masuda et al.,
1999b
), OAT-K2 (Masuda et al., 1999a
), oatp1 (Jacquemin et al., 1994
),
and oatp3 (Abe et al., 1998
). Among them, OAT-K1 and OAT-K2 were
reported to mediate bidirectional methotrexate transport (Saito et al.,
1996
; Masuda et al., 1999a
,b
), and the
Km value for OAT-K1-mediated
methotrexate transport was determined to be 1.0 µM (Masuda et al.,
1997
). Thus, the cloning of human homologs of these rodent transporters
and the functional analysis for the role of these transporters in apical methotrexate transport should be performed
Since various drugs tested in this study dose dependently inhibited
hOAT1-, hOAT3-, and hOAT4-mediated methotrexate uptake, it was
suggested that hOAT1, hOAT3, and hOAT4 are sites of drug interactions
between methotrexate and these drugs. Among these interactions, it
appears that those between methotrexate and salicylate, phenylbutazone,
indomethacin, or probenecid at hOAT3 may have clinical significance, as
follows. The total and unbound plasma concentrations of various drugs
are as listed in the Table 2. Therapeutically relevant concentrations
of unbound drugs in the plasma are thought to be within 5-fold of the
maximum steady-state concentrations of unbound drugs in the plasma
(Zhang et al., 2000
). Comparing the Ki
values with therapeutically relevant concentrations of unbound drugs in
the plasma, those for salicylate, phenylbutazone, indomethacin, and
probenecid were comparable. In addition, the Ki values obtained in the presence of
5% human serum albumin were comparable with total plasma
concentrations of salicylate, phenylbutazone, indomethacin, or
probenecid. Based on these, it was predicted that these drugs could
inhibit the hOAT3-mediated methotrexate uptake in vivo, leading to the
increased plasma concentration of methotrexate.
Uwai et al. (2000)
have already demonstrated that the
IC50 values of salicylate, ketoprofen, and
indomethacin for rat OAT1-mediated methotrexate uptake were 1410, 0.5, and 2.7 µM, respectively. However, we found that the
IC50 values of salicylate, ketoprofen, and
indomethacin for hOAT1-mediated methotrexate uptake were >2000, 1200, and >2000 µM, respectively (data not shown). This discrepancy in
findings may be due to the species difference, i.e., between rats and
humans. Compared with rat OAT1, the amino acid sequence of hOAT1
exhibited 86.0% homology (Sekine et al., 1997
). On the other hand, the
IC50 values of ibuprofen, ketoprofen, piroxicam, indomethacin, and probenecid for adefovir uptake in Chinese hamster ovary cells stably expressing hOAT1 were 8.0, 1.3, 20.5, 3.0, and 7.4 µM, respectively (Mulato et al., 2000
). The results were similar to
those for rat OAT1-mediated methotrexate uptake (Uwai et al., 2000
),
but much lower than those for hOAT1-mediated methotrexate uptake. The
discrepancy may be due to the fact that the
Km value for hOAT1-mediated adefovir
uptake was 23.8 µM (Ho et al., 2000
), whereas that for hOAT1-mediated
methotrexate uptake was 553.8 µM.
At present, the mechanism for the interaction between methotrexate and
ibuprofen, ketoprofen, or piroxicam, or penicillin G remains unclear.
It is possible that other transporters mediate methotrexate transport
and are responsible for drug interactions. Since protein-binding
displacement of methotrexate by NSAIDs except salicylate is generally
thought to account for more than a small transient increase in free
methotrexate concentration, protein binding changes would probably not
be of major clinical significance (Taylor and Halprin, 1977
). In
addition, since prostaglandin synthesis is stimulated to maintain the
glomerular filtration rate in the setting of prerenal volume
contraction (Ciabattoni et al., 1984
; Dunn, 1984
), NSAIDs may decrease
glomerular filtration of methotrexate as a result of inhibition of
prostaglandin synthesis (Kremer and Hamilton, 1995
). However, patients
who do not have a condition that predisposes them to activation of
renal prostaglandins would not have a decrease in renal function
following treatment with NSAIDs (Kremer and Hamilton, 1995
).
In conclusion, these results suggest that methotrexate is taken up in the basolateral membrane by hOAT3 and hOAT1, and taken up or effluxed in the apical membrane of the proximal tubule via hOAT4. In addition, hOAT1, hOAT3, and hOAT4 were sites of drug interactions between methotrexate and NSAIDs, probenecid, and penicillin G. Furthermore, it was predicted that hOAT3 is a site of drug interactions between methotrexate and salicylate, phenylbutazone, indomethacin, or probenecid in vivo. Stable cells established in this study provide a good opportunity for evaluating drug interaction of methotrexate and newly developed drugs, particularly NSAIDs, in the preclinical stage.
| |
Footnotes |
|---|
Accepted for publication April 8, 2002.
Received for publication February 20, 2002.
This study was supported in part by grants-in-aid from the Ministry of Education, Sports, Science and Technology (11671048, 11694310, and 13671128), the Science Research Promotion Fund of the Japan Private School Promotion Foundation, and Research on Health Sciences focusing on Drug Innovation from Japan Health Sciences Foundation.
DOI: 10.1124/jpet.102.034330
Address correspondence to: Dr. Hitoshi Endou, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi Tokyo 181-8611, Japan. E-mail: endouh{at}kyorin-u.ac.jp
| |
Abbreviations |
|---|
NSAID, nonsteroidal anti-inflammatory drug; OAT, organic anion transporter; hOAT, human organic anion transporter; OAT-K1, OAT-K2, renal organic anion transporter 1 and 2; oatp1, oatp2, organic anion-transporting polypeptide 1 and 2; MRP2, multidrug resistance protein 2; NPT1, human type I sodium-dependent inorganic phosphate transporter; S1, S2, S3, the first, second, and third segment of proximal tubule; D-PBS, Dulbecco's modified phosphate-buffered saline; hPAHT, human kidney p-aminohippurate transporter.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Heredi-Szabo, H. Glavinas, E. Kis, D. Mehn, G. Bathori, Z. Veres, L. Kobori, O. von Richter, K. Jemnitz, and P. Krajcsi Multidrug Resistance Protein 2-Mediated Estradiol-17{beta}-D-glucuronide Transport Potentiation: In Vitro-in Vivo Correlation and Species Specificity Drug Metab. Dispos., April 1, 2009; 37(4): 794 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fukuda, R. Ohashi, M. Tsuda-Tsukimoto, and I. Tamai Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1275 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1162 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, J. B. Koenderink, and F. G. M. Russel Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tahara, H. Kusuhara, K. Maeda, H. Koepsell, E. Fuse, and Y. Sugiyama INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID Drug Metab. Dispos., May 1, 2006; 34(5): 743 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bakhiya, M. Stephani, A. Bahn, B. Ugele, A. Seidel, G. Burckhardt, and H. Glatt Uptake of Chemically Reactive, DNA-Damaging Sulfuric Acid Esters into Renal Cells by Human Organic Anion Transporters J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1414 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Anzai, P. Jutabha, A. Enomoto, H. Yokoyama, H. Nonoguchi, T. Hirata, K. Shiraya, X. He, S. H. Cha, M. Takeda, et al. Functional Characterization of Rat Organic Anion Transporter 5 (Slc22a19) at the Apical Membrane of Renal Proximal Tubules J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 534 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Dai, Y. Chen, and W. F. Elmquist Distribution of the Novel Antifolate Pemetrexed to the Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 222 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Srimaroeng, V. Chatsudthipong, A. G. Aslamkhan, and J. B. Pritchard Transport of the Natural Sweetener Stevioside and Its Aglycone Steviol by Human Organic Anion Transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8) J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 621 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Burckhardt, J. Lorenz, C. Kobbe, and G. Burckhardt Substrate specificity of the human renal sodium dicarboxylate cotransporter, hNaDC-3, under voltage-clamp conditions Am J Physiol Renal Physiol, April 1, 2005; 288(4): F792 - F799. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions Cancer Res., August 15, 2004; 64(16): 5804 - 5811. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhao, M. Hanscom, S. Chattopadhyay, and I. D. Goldman Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier: Association with the Presence of a Secondary Transport Pathway Cancer Res., May 1, 2004; 64(9): 3313 - 3319. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zhou, K. Tanaka, Z. Pan, J. Ma, and G. You The Role of Glycine Residues in the Function of Human Organic Anion Transporter 4 Mol. Pharmacol., May 1, 2004; 65(5): 1141 - 1147. [Abstract] [Full Text] |
||||
![]() |
Y. Nozaki, H. Kusuhara, H. Endou, and Y. Sugiyama Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 226 - 234. [Abstract] [Full Text] |
||||
![]() |
S. A. Eraly, K. T. Bush, R. V. Sampogna, V. Bhatnagar, and S. K. Nigam The Molecular Pharmacology of Organic Anion Transporters: from DNA to FDA? Mol. Pharmacol., March 1, 2004; 65(3): 479 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kneuer, K. U. Honscha, and W. Honscha Sodium-dependent methotrexate carrier-1 is expressed in rat kidney: cloning and functional characterization Am J Physiol Renal Physiol, March 1, 2004; 286(3): F564 - F571. [Abstract] [Full Text] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nzila, E. Mberu, P. Bray, G. Kokwaro, P. Winstanley, K. Marsh, and S. Ward Chemosensitization of Plasmodium falciparum by Probenecid In Vitro Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2108 - 2112. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||